EG 427
French tech company | Builders Republic
About
Clinical-stage biotech developing gene therapies for chronic urological and neurological diseases — built on a non-replicating herpes (HSV-1) vector platform that delivers genetic medicine to selectively silence overactive sensory nerves, with a lead program targeting overactive and neurogenic bladder.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series B
- Founded
- 2019
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 27 M€ raised since 2020
Funding rounds
- Series B — 2025